(29 Jan 2007) SHOTLIST
1. Exterior shot of Taiwan's National Health Research Institute
2. Wide shot of press conference
3. SOUNDBITE: (English) Pele Chong, director of Vaccine Research and Development Centre, Taiwan's National Health Research Institute:
"This is in bulk. This has not has not been formulated in the final for injection yet. This is the bulk material because we don't know what's the best formulation yet, but we have used the so-called Alum, is the adjuvant allowed for human use, for the formulation currently. And it shows some protection advocacy in the animal."
4. Close-up of two bottles of H5N1 vaccine bulk
5. Close-up of label on bottle reading "H5N1 avian flu vaccine bulk"
6. SOUNDBITE: (Mandarin) Su Yi-jen, director of Vaccine Research and Development Centre, Taiwan's National Health Research Institute:
"For the part of cell cultivation, we now have this know-how that a chemical called M-compound can help in cultivating cells. In the cell cultivation, there is sometimes a limit in producing cells. So we now use the chemical so that it can speed up the cell cultivation by four times."
7. Cutaway of cameraman
8. Wide shot of news conference
9. Mid shot of projection on screen during press conference
10. SOUNDBITE: (Mandarin) Su Yi-jen, director of Vaccine Research and Development Centre, Taiwan's National Health Research Institute:
"We target the annual production at one million doses. If we are fast enough to produce 200-thousand in three months, that means if we follow the schedule, we can complete this production at the end of this year."
11. Various of laboratory
12. Wide shot of Chong in laboratory
13. SOUNDBITE: (English) Pele Chong, director of Vaccine Research and Development Centre, Taiwan's National Health Research Institute:
"We are using very little amount of material in the so called animal chance study. We used 0.1 microgramme dose, we have over 70 percent protection. So we just did the first trials. Now we are doing optimum doses to see which dose will give us a hundred percent protection."
14. Various of researchers in laboratory
STORYLINE:
Taiwan said on Monday it has developed a high-yield, safe bird flu vaccine, becoming one of the countries near the stage of producing a vaccine against the H5N1 virus.
Taiwan's National Health Research Institute succeeded recently in developing the vaccine after 17 months of research.
The team had to start from "ground zero" because Taiwan had not engaged in similar programmes before, said Pele Chong, who leads the vaccine development programme at the institute.
Chong said it took 4 months to set up the laboratory, and another 13 months to develop the vaccine.
Taiwan has not reported any human cases of the deadly H5N1 bird flu virus, but several fowl smuggled from China tested positive in 2005.
Singapore, China and India are researching bird flu vaccines, following the lead of Western pharmaceutical firms.
In case a bird flu epidemic should break out in Taiwan, the state-funded agency will have the capability to produce small amounts of the vaccine in its laboratory and give limited injections to poultry farmers and medical personnel, institute officials said.
A production line will be built by the end of the year and formal production is expected to begin in late 2008 following months of human clinical tests, they said.
"If we are fast enough to produce 200-thousand in three months, that means if we follow the schedule, we can complete this production at the end of this year," said Su Yi-jen, the director of Vaccine Research and Development Centre.

Find out more about AP Archive: [ Ссылка ]
Twitter: [ Ссылка ]
Facebook: [ Ссылка ] ​​
Instagram: [ Ссылка ]


You can license this story through AP Archive: [ Ссылка ]

свернуть